非酒精性脂肪性肝病患者冠心病全球患病率、危险因素与筛查的荟萃分析
该荟萃分析纳入38篇文献,评估非酒精性脂肪性肝病(NAFLD)患者中冠心病的全球患病率、独立危险因素及脂肪变程度对冠心病表现的影响。结果显示NAFLD患者冠心病合并患病率为44.6%(95%CI 36.0%-53.6%),中重度脂肪变患者冠心病患病率高于轻度脂肪变患者。
要点
- NAFLD患者冠心病合并患病率44.6%,显著高于对照人群(OR 1.33)。
- 亚临床冠心病患病率38.7%,临床冠心病患病率55.4%。
- 中重度脂肪变患者冠心病患病率37.5%,高于轻度脂肪变患者的29.6%。
核心结论
- 脂肪变与冠心病受累相关,中重度脂肪变与临床冠心病相关。
- NAFLD患者应早期筛查冠心病并及时干预以提供整体照护。
研究设计与样本
- 荟萃分析,检索Embase和Medline数据库,纳入38篇文献,其中14篇报告临床冠心病、24篇报告亚临床冠心病。
- 共纳入67,070例NAFLD患者,提取数据包括地区、诊断方法、基线特征、冠心病患病率及严重程度、NAFLD严重程度和危险因素。
主要发现
- NAFLD患者冠心病合并患病率为44.6%(95%CI 36.0%-53.6%),OR为1.33(95%CI 1.21%-1.45%,P<.0001)。
- 中重度脂肪变患者冠心病患病率为37.5%(95%CI 15.0%-67.2%),轻度脂肪变患者为29.6%(95%CI 13.1%-54.0%)。
- 亚临床冠心病合并患病率为38.7%(95%CI 29.8%-48.5%),临床冠心病合并患病率为55.4%(95%CI 39.6%-70.1%)。
临床怎么用
- 对NAFLD患者应早期筛查冠心病并及时干预,以实现整体照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cardiovascular disease remains the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Studies examining the association of coronary heart disease (CHD) and NAFLD are cofounded by various cardiometabolic factors, particularly diabetes and body mass index. Hence, we seek to explore such association by investigating the global prevalence, independent risk factors, and influence of steatosis grade on manifestation of CHD among patients with NAFLD. METHODS: Two databases, Embase and Medline, were utilized to search for articles relating to NAFLD and CHD. Data including, but not limited to, continent, diagnostic methods, baseline characteristics, prevalence of CHD, CHD severity, NAFLD severity, and risk factors were extracted. RESULTS: Of the 38 articles included, 14 reported prevalence of clinical coronary artery disease (CAD) and 24 subclinical CAD. The pooled prevalence of CHD was 44.6% (95% confidence interval [CI], 36.0%-53.6%) among 67,070 patients with NAFLD with an odds ratio of 1.33 (95% CI, 1.21%-1.45%; P < .0001). The prevalence of CHD was higher in patients with moderate to severe steatosis (37.5%; 95% CI, 15.0%-67.2%) than those with mild steatosis (29.6%; 95% CI, 13.1%-54.0%). The pooled prevalence of subclinical and clinical CAD was 38.7% (95% CI, 29.8%-48.5%) and 55.4% (95% CI, 39.6%-70.1%), respectively. CONCLUSION: Steatosis was found to be related with CHD involvement, with moderate to severe steatosis related to clinical CAD. Early screening and prompt intervention for CHD in NAFLD are warranted for holistic care in NAFLD.
引用
- Toh JZK, Pan XH, Tay PWL, et al. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2021. PMID: 34560278. doi:10.1016/j.cgh.2021.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。